Find information on thousands of medical conditions and prescription drugs.

Streptokinase

Streptokinase is an extracellular metallo-enzyme produced by beta-haemolytic streptococcus and is used as an effective and cheap clot-dissolving medication in some cases of myocardial infarction (heart attack) and pulmonary embolism. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Growth hormone
Salbutamol
Salmeterol
Sandimmune
Sandostatin
Sansert
Saquinavir
Sarafem
Satric
Scopolamine
Seasonale
Secobarbital
Secretin
Selegiline
Semprex-D
Sensipar
Sensorcaine
Serax
Serevent
Serine
Seroquel
Serostim
Serrapeptase
Sertindole
Sertraline
Serzone
Sevelamer
Sevoflurane
Sibutramine
Sildenafil
Silibinin
Simvastatin
Sinemet
Sinequan
Singulair
Sirolimus
Skelaxin
Sodium cyclamate
Solage
Soma
Somatostatin
Sotahexal
Sotalol
Sotret
Spiperone
Spiriva
Spironolactone
Sporahexal
Sporanox
SPS
SSD
Stanozolol
Stavudine
Stelazine
Stilbestrol
Stilbetin
Stimate
Stiripentol
Strattera
Streptokinase
Streptomycin
Suboxone
Subutex
Sucralfate
Sucralfate
Sufentanil
Sulbactam
Sulfamethoxazole
Sulfanilamide
Sulfasalazine
Sulforidazine
Sulla
Sulpiride
Sultamicillin
Sumatriptan
Suprefact
Suramin sodium
Sustaire
Sustiva
Suxamethonium chloride
Symmetrel
Synarel
Synercid
Synthroid
Syntocinon
Zaleplon
T
U
V
W
X
Y
Z

It belongs to a group of medicines known as fibrinolytics, and works by cleaving plasminogen and producing plasmin.

Plasmin is produced in the blood to break down the major constituent of blood clots fibrin, therefore dissolving clots once they have fulfilled their purpose in stopping bleeding. Extra production of plasmin caused by streptokinase breaks down unwanted blood clots, for example, in the lungs (pulmonary embolism).

It is given intravenously as soon as possible after the onset of a heart attack (acute phase - myocardial infarction) to dissolve clots in the arteries of the heart wall. This reduces the amount of damage to the heart muscle. Streptokinase is a bacterial product so the body will build up an immunity to it. It is recommended that this medicine should not be used again after four days from the first administration, as it may not be as effective and can also cause an allergic reaction. For this reason, it is usually given only for a person's first heart attack.

Read more at Wikipedia.org


[List your site here Free!]


Streptokinase for Endobronchial Blood Clots
From CHEST, 8/1/99 by Arvind Bansal

To the Editor:

Dr. Arney and colleagues (January 1999)[1] reported their experience with the management of endobronchial blood clots.[1] The authors also reviewed the literature concerned with this subject, including reports of the benefit of topical thrombolytic administration Although examples of the recurrence of bleeding following the use of topical streptokinase were not uncovered within their library search, we indeed reported such a case 10 years ago.[2] The patient had squamous cell carcinoma of the lung and required mechanical ventilation for massive hemoptysis associated with refractory hypoxemia. Following the use of a Swan-Ganz catheter to tamponade the left mainstem bronchus for hemorrhage, an endotracheal (ET) tube blood clot developed, resulting in life-threatening ventilatory failure. Although 100,000 IU of streptokinase was topically applied down the ET tube, thereby relieving the obstruction, later (4.5 h) the patient died of exsanguinating hemorrhage. Three hours after the patient's death, the blood in the ventilator tubing remained unclotted.

It appears that streptokinase in a bolus of 100,000 U can be absorbed from the airway mucosa and result in a systemic lytic state. It is possible that a lower dose, diluted with saline solution and administered in small aliquots, can be safer, as mentioned by the authors. Time may not be on the patient's side, however, if the airway clot is in the trachea or in the ET tube. We agree with Dr. Arney that extreme caution must be used when thrombolytic agents are instilled into the airway, and management needs should be considered, including cryoprecipitates in advance of administering these agents.

Arvind Bansal, MD Robert D. Brandstetter, MD, FCCP Sound Shore Medical Center New Rochelle, NY

Correspondence to: Robert D. Brandstetter, MD, FCCP, Sound Shore Medical Center, 16 Guion Place, New Rochelle, NY 10802

REFERENCES

[1] Arney KL, Judson MA, Sahn SA. Airway obstruction arising from blood clot: three reports and a review of the literature. Chest 1999; 115:293-300

[2] Brandstetter RD. The use of Swan-Ganz catheter and streptokinase in the management of massive hemoptysis. NY State J Med 1990; 1:33-35

COPYRIGHT 1999 American College of Chest Physicians
COPYRIGHT 2000 Gale Group

Return to Streptokinase
Home Contact Resources Exchange Links ebay